<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580994</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1417-LCG</org_study_id>
    <secondary_id>2014-003090-42</secondary_id>
    <nct_id>NCT02580994</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Untreated Extensive SCLC</brief_title>
  <acronym>REACTION</acronym>
  <official_title>REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab (MK-3475) in Untreated Extensive Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, two armed, controlled, and randomized phase II trial
      investigating the activity of pembrolizumab (MK-3475) in combination with standard
      chemotherapy in Extensive Disease (ED)-SCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, two armed, controlled, and randomized phase II trial
      investigating the activity of pembrolizumab (MK-3475) in combination with standard
      chemotherapy in ED-SCLC.

      Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the
      informed consent, and then centrally randomized 1:1 to the experimental arm (Arm A) and the
      control arm (Arm B).

      Cross-over at the time of disease progression will be allowed for arm B only.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Small Cell Lung Cancer (SCLC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles of cis/carboplatin and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion at the dose of 200 mg on day 1</description>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis/carboplatin and etoposide</intervention_name>
    <description>Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3</description>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed SCLC

          -  Extended disease according to the criteria of the Veteran's Administration - Lung
             Cancer Group (VALG)

          -  No prior systemic therapy for SCLC

          -  Measurable disease

          -  Previous palliative brain radiotherapy is allowed if terminated at least 3 weeks
             before treatment start

          -  Partial or complete response according to RECIST (Response Evaluation Criteria in
             Solid Tumors) 1.1 after 2 cycles of any platinum-based induction chemotherapy regimen

        Exclusion Criteria:

          -  Performance Status 3-4

          -  No adequate organ function

          -  Less than 3 month life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Besse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedicte Marchal</last_name>
    <phone>+32 2 774 10 78</phone>
    <email>benedicte.marchal@eortc.be</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 11, 2016</lastchanged_date>
  <firstreceived_date>October 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>randomized</keyword>
  <keyword>pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
